Dutch biotechnology company Crucell N.V. and allied contract manufacturer DSM Biologics have signed a PER.C6 research license agreement with Danish biotechnology company Symphogen A/S. This license agreement allows Symphogen to evaluate and use the PER.C6 cell line for production of its proprietary recombinant polyclonal antibodies, known as symphobodies.

Symphogen has opted to evaluate the PER.C6 cell line for use with Sympress, its proprietary expression platform, for consistent manufacturing of its symphobody compositions.

Under the terms of the agreement, Symphogen will pay a signing fee and annual maintenance fees. Further financial details are not disclosed.

"We are very pleased that Symphogen has chosen to evaluate the PER.C6 cell line for the manufacturing of its symphobody compositions," Crucell CEO Dr Ronald Brus said adding, "This agreement further validates the quality of our cell line technology and we look forward to working with Symphogen."